La cadena de opciones muestra datos clave de las opciones de acciones de TNL Mediagene a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para TNL Mediagene..

TNL Mediagene (NASDAQ:TNMG) Bolsa, Cadena de Opciones

TNL Mediagene

TNL Mediagene is principally engaged in digital advertising, integrated marketing, marketing survey, artificial intelligence technology, data analysis, content service platform and production of audio-visual programs. Geographically, the company generates the majority of its revenue from Taiwan.

Movimiento de acciones

AEHL

AMBC

BTOG

CCCS

DGICA

EHAB

FFIC

FMTO

IXHL

RNAC

SDHC

SVRE

TNMG

VERO

VINC

VNOM

WORX

Acciones en alza y en caída antes del mercado: descubre qué impulsó los mayores movimientos bursátiles del día.

Acciones de Venus Concept (VERO) se disparan un 200%; aquí están 20 acciones que se mueven en premercado

News

Intraday Update

Markets

Movers

Trading Ideas

ALUR

AUID

BHAT

BNTC

GCTK

INNV

MCVT

OUST

PNBK

PSTV

RVSB

USAR

XHLD

Ouster sorprende con resultados mejores de lo esperado y sus acciones suben un 8,95%. Descubre las acciones que dominan el premercado.

Las acciones de Ouster (OUST) suben un 9%; Aquí están 20 acciones que se mueven en el premercado de EE.UU.

Pre-Market Outlook

ADTX

APTO

CSAI

DSGN

EFOI

EWCZ

GLYC

GRAB

HEES

INLF

LVWR

MGOL

MTRX

NESR

NTIC

RSLS

Las acciones de GCL Global suben más del 100% en premercado tras su fusión. Descubre qué otras acciones están en movimiento hoy.

Acciones de GCL Global Holdings (GCL) se disparan un 107%; 20 acciones que se mueven en el premercado

Politics

Economics

General

iShares MSCI Israel Capped Investable Market Index Fund

Reuters Cites Military Sources Saying Air Defense System Activated In US Ain Al-Asad Airbase In Iraq For Fear Of A Potential Attack; Maximum Alert Status Declared, Orders Issued To Take Shelter In Bunkers At Ain Al-Asad Airbase In Iraq

WIIM

SCHL

Scholastic shares are trading higher after the company issued FY25 adjusted EBITDA results.

RNEW

Trading Halt: Halted at 12:49:24 p.m. ET - Trading Halt: Halt News Pending

CAPR

Capricor Therapeutics shares are trading lower after Oppenheimer maintained an Outperform rating on the stock and lowered its price target from $43 to $22.

CLBR

Colombier Acquisition Corp. II shares are trading higher after the SEC declared the registration statement on Form S-4 in connection with its proposed business combination with GrabAGun effective.

Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock is trading lower on Monday, with a session volume of 1.9 million compared to an average volume of 2.41 million, as per <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">data from Benzinga Pro</a>.
According to a Friday media report, Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research (CBER), canceled the advisory committee meeting for the company's cell therapy for Duchenne muscular dystrophy.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46036263/capricor-reports-4-year-data-for-deramiocel-shows-sustained-benefit-in-duchenne-patients" rel="noreferrer noopener">Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients</a>
Earlier in June, the FDA&#8217;s Pre-License Inspection (PLI) of its San Diego manufacturing facility for Deramiocel, the company&#8217;s lead cell therapy candidate with a Biologics License Application (BLA) under FDA review for potential approval in the treatment of <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Duchenne Muscular Dystrophy (DMD)</a>.
The FDA informed Capricor of its intent to hold the Advisory Committee meeting on July 30, 2025, although that date is pending confirmation by the FDA. At the time of the mid-cycle review, no significant issues or major <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45882991/capricor-therapeutics-announces-key-regulatory-updates-for-its-duchenne-muscular-dystrophy-program" rel="noreferrer noopener">deficiencies were noted</a>.
The BLA for Deramiocel remains under priority review with a Prescription Drug User Fee Act (PDUFA) action date of August 31, 2025.
STAT News <a href="https://www.statnews.com/2025/06/20/fda-ouster-top-gene-therapy-official-nicole-verdun-placed-on-leave-after-review-committee-canceled/">reported </a>that the FDA removed its top official overseeing cell and gene therapies shortly after a dispute with her superior over a treatment for Duchenne muscular dystrophy.
The official, Nicole Verdun, had planned to convene an advisory committee meeting to evaluate a therapy developed by Capricor Therapeutics. However, to STAT, Prasad — her superior — doubted the treatment's effectiveness and canceled the meeting, citing sources familiar with the matter.
The report also noted that some sources described ongoing tensions surrounding Verdun's management style, adding uncertainty about the reasons she was placed on leave.
Since the report on Friday, Capricor stock has plunged almost 30%.
Alliance for Regenerative Medicine (ARM), an advocacy organization, <a target="_blank" href="https://alliancerm.org/press-release/statement-on-the-departure-of-otp-director/" rel="noreferrer noopener">said</a> with five regulatory decisions pending on cell and gene therapy (CGT) products in 2025 and a burgeoning pipeline of nearly 2,000 CGT clinical trials ongoing globally, CBER and OTP must operate at the highest level of productivity, efficiency, and scientific rigor.
Price Action: CAPR stock is down 11.6% at $7.30 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46050655/novo-nordisks-weight-loss-injection-cagrisema-data-sparks-investors-concern" target="_blank" rel="noreferrer noopener">Novo Nordisk&#8217;s Weight Loss Injection CagriSema Data Sparks Investor Concern</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Biotech

Health Care

Why Is Capricor Therapeutics Stock Trading Lower On Monday?

DJT stock has given up its prior gain. Trump Media shares were trading higher after the company announced a $400 million share repurchase authorization.

ZYBT

Zhengye Biotechnology Holding shares are trading lower after the company announced it received a Nasdaq noncompliance notice.

Rumors

Reuters Citing A Witness Says Explosions Heard Over Qatar Capital Doha

JP Morgan analyst Jeremy Tonet maintains Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) with a Overweight and raises the price target from $311 to $380.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Constellation Energy, Raises Price Target to $380

<a href="https://x.com/barakravid/status/1937188213875180015?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/barakravid/status/1937188213875180015?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

Global Affairs Correspondent For Axios Barak Ravid Posts on X"Israeli official tells me Iran launched 6 missiles towards U.S. bases in Qatar"

U.S. bonds are on track to log ten straight six-month periods of underperformance relative to stocks, a record-breaking stretch of underperformance since 2020 that&#8217;s rippling through markets and shaking <a href="https://www.benzinga.com/topic/stories-that-matter">up traditional investor portfolios.</a>
The streak spans five years and reflects a regime shift in global markets—one driven by rising interest rates, an overstretched fiscal backdrop, and a tech-driven equity boom.
Yet with geopolitical tensions escalating in Iran, some may wonder whether the prolonged cycle of bond underperformance compared to stocks might finally turn.
See Also: <a href="https://www.benzinga.com/news/25/06/46055156/sp500-oil-crisis-performance-iran">War, Oil, And S&amp;P 500: Here&#8217;s How The Stock Market Behaves In Energy Crises</a>
<h3 class="wp-block-heading">Bond Market Underperformance</h3>
A way to assess the relative performance of the bond market compared to the stock market is by tracking the ratio between the iShares 20+ Year Treasury Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NYSE">TLT</a>) and the Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>); below is a table showing this dynamic over the past 10 consecutive half-year periods.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Period</th>
<th>TLT/VOO Ratio</th>
<th>TLT Return</th>
<th>S&amp;P 500 Return</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020 H2</td>
<td>-20.65%</td>
<td>-3.80%</td>
<td>+21.30%</td>
</tr>
<tr>
<td>2021 H1</td>
<td>-20.07%</td>
<td>-8.48%</td>
<td>+14.50%</td>
</tr>
<tr>
<td>2021 H2</td>
<td>-7.46%</td>
<td>+2.70%</td>
<td>+10.94%</td>
</tr>
<tr>
<td>2022 H1</td>
<td>-2.44%</td>
<td>-22.48%</td>
<td>-20.54%</td>
</tr>
<tr>
<td>2022 H2</td>
<td>-14.43%</td>
<td>-13.33%</td>
<td>+1.29%</td>
</tr>
<tr>
<td>2023 H1</td>
<td>-10.81%</td>
<td>+3.39%</td>
<td>+15.92%</td>
</tr>
<tr>
<td>2023 H2</td>
<td>-10.44%</td>
<td>-3.94%</td>
<td>+7.25%</td>
</tr>
<tr>
<td>2024 H1</td>
<td>-18.93%</td>
<td>-7.18%</td>
<td>+14.50%</td>
</tr>
<tr>
<td>2024 H2</td>
<td>-11.68%</td>
<td>-4.85%</td>
<td>+7.73%</td>
</tr>
<tr>
<td>2025 H1 (thru June 23)</td>
<td>-2.15%</td>
<td>-0.10%</td>
<td>+2.05%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data: TradingView</figcaption></figure>
<h3 class="wp-block-heading">Chart: TLT vs. VOO – A 70% Underperformance Over Five Years</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="528" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23115259/image-336-1024x528.png" alt="" class="wp-image-958379" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23115259/image-336-1024x528.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23115259/image-336-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23115259/image-336-768x396.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23115259/image-336-1536x792.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23115259/image-336-2048x1056.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Why Have Bonds Struggled?</h3>
It all started with the 2020 pandemic recovery, when a "risk-on" mood emerged.
As stimulus measures boosted economic growth, investors fled safe-haven Treasuries and flocked to risk-on assets like equities.
The real damage accelerated in 2022, when the Federal Reserve launched its most aggressive rate-hiking cycle in decades. Bond prices collapsed as yields surged, marking the end of a four-decade bull run fueled by low inflation and near-zero interest rates since the 2008 financial crisis.
Even in the first half of 2022, as the S&amp;P 500 plunged 20.5%, long-duration Treasuries fell even harder—down 22.5%—highlighting how vulnerable bonds had become in a rising-rate environment.
The contrast grew starker in 2023 and 2024, when stocks entered a blistering bull market—posting back-to-back annual gains of 24% and 23%, the strongest two-year stretch since 1998. Bonds, meanwhile, remained under pressure as yields stayed elevated.
Behind the scenes, U.S. fiscal conditions worsened. Since the pandemic, the federal deficit has hovered near 6%-7% of GDP, far above historical norms. In 2025, credit rating agency Moody's stripped the U.S. of its last AAA rating, citing runaway spending and debt accumulation. Yields on 30-year Treasury bonds escalated at or near 5%. 
Adding fuel to the fire, President Donald Trump's sweeping fiscal package has pushed long-term projections deeper into the red. According to the Congressional Budget Office, the bill is expected to add $2.6 trillion to the deficit over the next decade.
Together, these forces have created a toxic mix for bonds: rising rates, sticky inflation, surging deficits and a loss of investor confidence in U.S. fiscal sustainability.
<h3 class="wp-block-heading">Will War Shift The Bond-Stock Balance?</h3>
With geopolitical risk surging after the U.S. struck Iran's nuclear facility on June 21, investors are asking a key question: Could a major war or energy crisis finally reverse bonds' historic underperformance versus equities?
According to Mark Cabana, rates strategist at Bank of America, the relationship between conflict and Treasury yields isn't straightforward. 
"UST yields often don&#8217;t decline with higher geopolitical risks, especially if oil prices are rising," he said in a note shared Monday.
The critical factor, Cabana added, is whether the event materially damages the U.S. economy. 
"Our analysis of prior geopolitical events suggests an inconsistent response of USTs; we conclude that USTs often do not rally amidst geopolitical tensions and the directional move correlates with oil prices."
Bank of America's historical study, which includes major geopolitical flashpoints from the 1990 Iraqi invasion of Kuwait onward, found that Treasury yields actually rose about half the time in the month following such events. 
Often, these periods were accompanied by oil price spikes, which fueled inflation concerns and pushed yields higher—not lower.
Put simply, the bond market doesn't behave like a risk-off hedge when oil is surging.
That's why even a significant military escalation in the Middle East may not be enough to snap the bond market's underperformance streak versus equities.
Now Read
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/46055156/sp500-oil-crisis-performance-iran">War, Oil, And S&amp;P 500: Here&#8217;s How The Stock Market Behaves In Energy Crises </a></li>
</ul>
Image: Shutterstock

Analyst Color

Equities

Government

Macro Economic Events

Regulations

Bonds

Broad U.S. Equity ETFs

Treasuries

Econ #s

Federal Reserve

ETFs

iShares Trust Barclays 20+ Year Treasury Bond Fund

US Bonds Trailed S&P 500 For 5 Straight Years — Will Iran Shock Snap The Streak?

<a href="https://www.cbsnews.com/news/compass-sues-zillow-ban-real-estate-mls-listings-antitrust-monopoly/" title="https://www.cbsnews.com/news/compass-sues-zillow-ban-real-estate-mls-listings-antitrust-monopoly/">https://www.cbsnews.com/news/compass-sues-zillow-ban-real-estate-mls-listings-antitrust-monopoly/</a>

Legal

COMP

Earlier: Compass Announces It Has Sued Zillow In Federal Court, Accusing It Of Violating Antitrust Laws- CBS News

JBLU

Shares of airline stocks are trading lower on uncertain travel demand outlook following US strikes on Iran. Qatar has closed airspace amid tensions.

For us long-term investors, we may find ourselves having to sell some stocks during a market drawdown.
It's an unpleasant thought I've had since early April, when the S&amp;P 500&nbsp;<a href="https://www.tker.co/p/bear-markets-in-context">fell by around 20%</a>&nbsp;from its Feb. 19 all-time high.
But does it always make sense to think of a 20% decline in your stock portfolio as a loss?
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/$s_!REku!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7b842e8d-167d-4d70-9ddd-2406a287b164_932x453.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/$s_!REku!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7b842e8d-167d-4d70-9ddd-2406a287b164_932x453.png" alt="" /></a><figcaption class="wp-element-caption">2025 has been rough. (Source: Yahoo Finance)</figcaption></figure>
A common answer is that it's not a loss until you sell. This is the distinction between a&nbsp;<a href="https://www.investopedia.com/ask/answers/04/021204.asp">realized loss and an unrealized loss</a>.
But even if you sell during a bear market, do you really lose 20%?
For many long-term investors, there's a case to be made that the answer is&nbsp;no.
<h2 class="wp-block-heading">Reframing how we think about market drawdowns &#x1f914;</h2>
At its April 7 intraday bottom, the S&amp;P 500 reached a low of 4,835.04. This was the lowest level since Jan. 19, 2024.
In the context of my personal stock portfolio, which almost totally consists of purchases of S&amp;P 500 index funds, I made three observations at the time:
<ul class="wp-block-list">
<li>All of my trades since January 2024 were in the red.</li>
<li>All of my trades from 2005, when I opened my first 401(k) account, through 2023 were profitable.</li>
<li>I put much more money to work from 2005 to 2023 than I did from 2024 to 2025.</li>
</ul>
To help understand this, see the chart below of the S&amp;P 500 since 2005. The dotted line demarcates the S&amp;P's April low of 4,835.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/$s_!ypvV!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F77432f10-8196-45c9-bcda-f664813ec82e_938x440.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/$s_!ypvV!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F77432f10-8196-45c9-bcda-f664813ec82e_938x440.png" alt="" /></a><figcaption class="wp-element-caption">The stock market has mostly performed very well since 2005. (Source: Yahoo Finance)</figcaption></figure>
Over 95% of the contributions I've made to my retirement accounts occurred when the stock market was much lower than the April 2025 low.
This means I still earned a substantial positive return investing in the stock market throughout my adult life. Even the purchases I made near market peaks before the global financial crisis and the COVID-19 pandemic were significantly profitable trades.
This is a roundabout way of saying that I'm thinking more about my&nbsp;<a href="https://www.investopedia.com/terms/c/costbasis.asp">cost basis</a>. Since I made most of my purchases when the stock market was much lower than where it's trading today, my average cost basis is very low.
<h2 class="wp-block-heading">This doesn't actually change anything, Sam &#x1f928;</h2>
To be clear, reframing how you think about the performance of your investments does not change the actual performance of your investments.
Sure, I'm still very much in the money. But there's also no denying that at the April 7 low, the value of my portfolio was still down about 20% from its peak.
If you are a stone-cold, totally rational investor, then this discussion was perhaps a waste of time. But I think most of us benefit from some perspective when faced with jarring drops in our portfolios.
For me, thinking about how much I'm up relative to my cost basis has been much more positive on my mental health than thinking about how much I'm down from the market's peak.
<a href="https://www.tker.co/p/stock-market-down-days-drawdowns-down-years-normal">Investing in the stock market is an unpleasant process</a>. We do what we can to cope with the tougher times.
&#x2A;&#x2A;
I joined Ryan Detrick and Sonu Varghese on the&nbsp;<a href="https://www.carsongroup.com/insights/blog/going-with-the-flow-with-sam-ro/">Facts vs. Feelings</a>&nbsp;podcast! We discussed economic signals, market psychology, data quality, AI, how to find great pizza in NYC, and more!
Catch it on&nbsp;<a href="https://open.spotify.com/episode/4stVNlfjvBLf8A6Cc2u0oo">Spotify</a>,&nbsp;<a href="https://podcasts.apple.com/us/podcast/going-with-the-flow-with-sam-ro-ep-140/id1651235114?i=1000713403750">Apple Podcasts</a>, and&nbsp;<a href="https://www.youtube.com/watch?v=Pdi0Nhtaw_k">YouTube</a>!
&#x2A;&#x2A;

Opinion

Is A 20% Decline In Your Portfolio A Loss? Does It Always Make Sense to Think So?

QNX, a subsidiary of BlackBerry Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>), and Vector Informatik have <a href="https://www.benzinga.com/pressreleases/25/06/ac46050181/qnx-and-vector-sign-memorandum-of-understanding-to-launch-foundational-vehicle-software-platform" target="_blank" rel="noreferrer noopener">signed a Memorandum of Understanding</a> (MoU) to jointly create a new software platform designed to support the development of software-defined vehicles (SDVs).
This next-generation solution will be designed to help accelerate the development of software-defined vehicles (SDVs) and reduce the complexity of automotive software integration.
Called the Foundational Vehicle Software Platform, the solution will merge Vector&#8217;s middleware and QNX&#8217;s safety-certified OS to create a streamlined base for applications running across vehicle ECUs.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44633991/blackberrys-qnx-secure-comms-growth-weighed-down-by-tariff-uncertainties-government-election-shifts-analyst" target="_blank" rel="noreferrer noopener">BlackBerry&#8217;s QNX, Secure Comms Growth Weighed Down By Tariff Uncertainties, Government Election Shifts: Analyst</a>
The platform will also incorporate Tech Auto&#8217;s MotionWise Schedule for the deterministic scheduling of components.
The goal is to reduce repetitive development work for automakers and foster faster delivery of vehicle software, all while aligning with key automotive safety and cybersecurity standards.
An early-access version will launch later this year for prototyping and partner feedback, with a fully certified release planned for late 2026.
The platform will be showcased at the Automobil-Elektronik Kongress on June 24–25 in Ludwigsburg, Germany. 
QNX COO John Wall said the project aims to &#8220;build smarter, safer vehicles, faster,&#8221; while Vector President Matthias Traub called it a step toward empowering the entire automotive ecosystem to create the next generation of intelligent vehicles.
Investors tracking developments in the software-defined vehicle space may also want to watch Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), along with ETFs such as Global X Autonomous &amp; Electric Vehicles ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIV#NASDAQ">DRIV</a>) and iShares U.S. Tech Breakthrough Multisector ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TECL#NYSE">TECL</a>).
Price Action: BB shares are trading higher by 1.06% to $4.28 at last check Monday.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46050967/trump-media-shares-move-higher-after-board-approves-400-million-buyback" target="_blank" rel="noreferrer noopener">Trump Media Shares Move Higher After Board Approves $400 Million Buyback</a></li>
</ul>
Photo by Michael Vi via Shutterstock

Tech

DRIV

NVDA

QCOM

TECL

BlackBerry's QNX, Vector Partner To Develop Next-Gen Vehicle Software Platform

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining over 50 points on Monday.
The Dow traded up 0.02% to 42,216.40 while the NASDAQ gained 0.35% to 19,514.58. The S&amp;P 500 also rose, gaining, 0.23% to 5,981.86.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 1.6% on Monday.
In trading on Friday, health care stocks fell by 0.3%.
Top Headline
The S&amp;P Global US services PMI fell to 53.1 in June versus 53.7 in the previous month, and compared to market expectations of 52.9.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>) shares shot up 386% to $1.76. Dr Ashleys Limited and Impact BioMedical Inc. announced a strategic merger.</li>
<li>Shares of SpartanNash Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPTN#NASDAQ">SPTN</a>) got a boost, surging 50% to $26.41 after the company announced it will be acquired by C&amp;S Wholesale Grocers.</li>
<li>Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares were also up, gaining 93% to $40.54 after the company announced positive topline results from its Phase 2b NAVIGATE trial evaluating CD388, a non-vaccine preventative of seasonal influenza.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares dropped 28% to $45.97 after Novo Nordisk reportedly terminated its collaboration with the company.</li>
<li>Shares of Lipella Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) were down 26% to $1.23. Lipella Pharmaceuticals announced delisting from Nasdaq Capital Market.</li>
<li>COMPASS Pathways plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) was down, falling 46% to $2.4901. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial.</li>
</ul>
Commodities In commodity news, oil traded down 1.1% to $73.05 while gold traded up 0.5% at $3,402.20.
Silver traded up 0.7% to $36.255 on Monday, while copper rose 0.1% to $4.8395.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.26%, while Spain's IBEX 35 Index fell 0.03%. London's FTSE 100 slipped 0.25%, Germany's DAX 40 declined 0.27% and France's CAC 40 fell 0.65% during the session.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei falling 0.13%, Hong Kong's Hang Seng Index gaining 0.67%, China's Shanghai Composite rising 0.65% and India's BSE Sensex falling 0.62%.
Economics
<ul class="wp-block-list">
<li>The S&amp;P Global US services PMI fell to 53.1 in June versus 53.7 in the previous month, and compared to market expectations of 52.9.</li>
<li>The S&amp;P Global US manufacturing PMI came in unchanged from the previous month at 52 in June.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46051985/amd-to-rally-more-than-36-here-are-10-top-analyst-forecasts-for-monday">AMD To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Eurozone

Commodities

CDTX

CMPS

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LIPO

SPTN

Crude Oil Falls 1%; US Services PMI Declines In June

A woman named Shelby recently called into &#8220;<a href="https://x.com/DaveRamsey/status/1934976756601049591">The Ramsey Show</a>&#8221; seeking clarity on a gut feeling she could no longer ignore: was her new boyfriend trying to <a href="https://www.benzinga.com/personal-finance/25/05/45491348/her-husband-lost-270k-in-a-crypto-scam-and-lied-about-itdave-ramseys-advice-pulled-no-punches">scam her with crypto</a>?
<h2 class="wp-block-heading">Pressuring Her To Cash Out Her 401(k)</h2>
Shelby told hosts Dave Ramsey and Jade Warshaw that she had been talking to a man for about a month. He claimed to have a lot more money than her and pushed her to cash out her 401(k) to fund a crypto investment. &#8220;He said he has this plan he&#8217;s been working on for about three years,&#8221; she said, and claimed she would get &#8220;90% back.&#8221; But when she expressed hesitation, he accused her of <a href="https://www.benzinga.com/personal-finance/25/04/44852424/you-could-literally-cost-yourself-millions-finance-expert-warns-against-panic-decision-on-trump-tariffs">making poor financial decisions</a>.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">When something doesn't feel right, it's usually because it isn't. <a href="https://t.co/xxCFddiMs9">pic.twitter.com/xxCFddiMs9</a>
&mdash; Dave Ramsey (@DaveRamsey) <a href="https://twitter.com/DaveRamsey/status/1934976756601049591?ref_src=twsrc%5Etfw">June 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
</ul>
Ramsey immediately flagged the situation. &#8220;It sounds like he&#8217;s really manipulating you here,&#8221; he said. Warshaw agreed, noting how emotional and pressured Shelby felt. &#8220;When something doesn&#8217;t feel right, it&#8217;s not right,&#8221; she told her.
Ramsey was straightforward: &#8220;You know why it smells bad? Because it stinks.&#8221;
Shelby admitted she had recently gotten out of a toxic relationship and had been hoping this new one would be different.&nbsp;
Ramsey didn't hesitate after that. &#8220;I&#8217;m not sure if he&#8217;s an idiot or a con man, but I am sure he&#8217;s one of the two,&#8221; he told her. &#8220;And my friend Shelby, who I love, doesn&#8217;t need to be dating a guy who&#8217;s an idiot or a con man. You&#8217;re done.&#8221;
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.
<h2 class="wp-block-heading">Then The Bombshell: They&#8217;ve Never Met In Person</h2>
The call took a sharp turn when Warshaw asked whether Shelby had actually met the man in real life. &#8220;Oh, um, well, it&#8217;s mostly online. I&#8217;ve been trying to meet him in person,&#8221; Shelby said.
Ramsey cut in: &#8220;You&#8217;ve never met him in person? Can you spell catfish? Does that all sound right to you? Or did you think we were going to tell you something else?&#8221; And Warshaw added, &#8220;That's the con man part.&#8221;
Warshaw reminded Shelby that she had called in for a reason. &#8220;I&#8217;m just agreeing with what your brain was already telling you,&#8221; she said.
Ramsey&#8217;s final word: &#8220;You deserve some love. This guy needs to be set straight, not you.&#8221;
See Also: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a>
<h2 class="wp-block-heading">What Dave Ramsey Thinks About Bitcoin</h2>
Ramsey has made his opinion on Bitcoin clear in past episodes. When asked last year if it should be treated like single stocks, he flat-out rejected the idea. "Bitcoin is a currency," he <a href="https://www.youtube.com/watch?v=IRUF0zOaZm0">said</a>.
He argued that Bitcoin has no intrinsic value and is backed only by perception and hype—a view shared by other prominent critics like economist <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40818582/gold-bull-peter-schiff-claims-bitcoin-lacks-intrinsic-value-and-is-destined-to-fail">Peter Schiff</a> and JPMorgan Chase&nbsp; CEO <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42940832/jamie-dimon-says-hes-not-against-blockchains-but-trades-guns-on-bitcoin-again-it-has-no-intrinsic-value-i-just-dont-feel-great-about">Jamie Dimon</a>.
&nbsp;"Currencies have no value except for their track record that indicates that two people are willing to fight over them," Ramsey said. He also pointed out that even Warren Buffett <a href="https://www.benzinga.com/news/management/25/01/43073354/warren-buffett-openly-called-bitcoin-a-rat-poison-in-2018-7-years-later-he-is-invested-in-this-crypto-linked-stock-which-soared-27-in-2024">won't invest in Bitcoin</a>. "If he doubled the amount he had put in Bitcoin, he would still have zero," Ramsey said, quoting Buffett.
He compared crypto to other speculative fads that come and go, calling Bitcoin "smoke and mirrors." Until it shows long-term stability and credibility, he doesn't consider it a serious financial asset.
Read Next: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
Image: Shutterstock

Personal Finance

A Woman Calls Dave Ramsey Worried Her Boyfriend Is A Crypto Scammer. His Tone Changes Completely When He Finds Out They've Never Met

Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 15 years by 4.17% on an annualized basis producing an average annual return of 16.49%. Currently, Cigna Group has a market capitalization of $85.39 billion. 
Buying $100 In CI: If an investor had bought $100 of CI stock 15 years ago, it would be worth $948.93 today based on a price of $314.95 for CI at the time of writing.
<h3>Cigna Group's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750696303_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Cigna Group 15 Years Ago Would Be Worth Today

Oppenheimer analyst Leland Gershell maintains Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Outperform and lowers the price target from $43 to $22.

Oppenheimer Maintains Outperform on Capricor Therapeutics, Lowers Price Target to $22

Press Releases

Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

TNL Mediagene Featured on McNallie Money Interview

Benchmark Initiates Research Coverage of TNL Mediagene

TNL Mediagene Co-Hosts the 2025 Generative AI Conference, Expands Presence in AI Ecosystem in Asia

TNL Mediagene to Participate in Maxim Group's 2025 Virtual Tech Conference: "Discover the Innovations Reshaping Tomorrow" on June 3-5, Provides Valuation Update

Entertainment

TNL Mediagene Progresses International Expansion: Roomie International Surpasses One Million Monthly Pageviews Within First Year

TNL Mediagene and WOWOW Expand Promotional Channels with New Model Linking Viewership to Purchases

TNL Mediagene (NASDAQ: TNMG) Commerce Business Surpasses $20 Million GMV in Five Months Through May, with Future Growth Expected from Strategic Partnership

TNL Mediagene Launches Business Insider Taiwan, Tapping Into Market of Over 1 Billion Mandarin Speakers Globally

Comments

TNL Mediagene

TNL Mediagene (TNMG) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL